Cel-Sci Overview
Latest ROE for Cel-Sci: -0.11% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-0.11%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Cel-Sci posts a ROE of -0.11%. That is below the Healthcare sector average of 22.76%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
For Healthcare stocks, a ROE near 22.76% is typical. Cel-Sci's -0.11% is lower that level. That is roughly 100.5% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.
Cel-Sci's ROE moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is -0.11%; use YoY and peer views to separate noise from signal.
Context for CVM's ROE usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 22.76%), and (3) consistency with growth and profitability. This page covers the first two; Cel-Sci's other metric pages and overview cover the third.
Judging Cel-Sci against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in ROE easier to interpret. Start with -0.11% here, then scan peer and history charts to see if the gap is persistent.
